“FORMULATION AND IN-VITRO EVALUATION OF FLOATING MATRIX TABLET OF FUROSEMIDE FOR ORAL CONTROLLED RELEASE”

Pharmaceutical

The aim of present study is The stomach and upper part of the small intestine are where furosemide is primarily absorbed when treating edema brought on by congestive heart failure (CHF), hepatic cirrhosis, renal impairment, and nephrotic syndrome. This narrow absorption window is responsible for furosemide’s limited oral bioavailability. Floating matrix tablet were prepared by direct compression technique using different Polymer with varying concentration. all polymer and drug were passed through sieve no.80 separately. Then drug were mixed in polybag for 5 min with the polymers and other ingredients in weight proportion as mentioned in Table 13. The powder blend was then lubricated with magnesium stearate and talc, and this lubricated blend were compressed into tablets using 8-mm flat-face on a 16 stationary rotary punching tablet machine with hardness in range of 5 to 5.5 kg/cm2. HPMC K4M and HPMC K100LV have predominant effect on drug release. HPMC K4M gives the good matrix integrity and retained drug release. HPMC K100LV along with HPMC K4M provides sustained and controlled drug release over the expected period of time. Sodium bicarbonate has predominant effect on the buoyancy lag time and also shows significant effect on drug release. In-vitro release rate studies showed that the minimum drug release was observed

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.